Ondexxya is the first approved reversal agent specifically for Factor Xa inhibitors, providing a major advance in the treatment of patients hospitalised with life-threatening bleeding
The award also follows GenScript's recognition at the Korea Bioprocessing Excellence Awards in 2021 for the "Best Contract Development and Manufacturing Organization Award".
A novel second-generation approach to achieve a safe, durable, and stable transgene expression to overcome the challenges of factor VIII replacement therapies
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
It also empowers domestic precision immunotherapy for tumours and promotes the high-quality development of China's biopharmaceutical industry
Recommendation based on Phase III PROVENT trial showing a significant reduction in the risk of developing symptomatic COVID-19, with protection lasting at least six months
The accelerated use of technology in clinical trials and the shift towards virtual trials is here to stay
As part of this partnership, Huma and AstraZeneca will launch Software as a Medical Device (SaMD) companion apps targeted at several therapeutic areas and will partner to help accelerate the adoption of decentralized clinical trials
The expansion makes Exothera one of the largest viral vector facilities in Europe
Sputnik Light is the first component of Sputnik V
Subscribe To Our Newsletter & Stay Updated
